FDA's Gottlieb Applauds Drug Rebates At Point-Of-Sale
The US FDA commissioner called recent initiatives to get drug rebates to patients at point-of-sale "healthy" public policy, and suggested insurance premiums have been subsidized by sick patients, addressing CNBC's health care conference.
You may also be interested in...
340B Hospitals May Be Losing Transparency Debate In Congress
Biopharma industry's arguments on rebate pass-through to patients appear to carry the day at Senate HELP Committee hearing.
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.
UnitedHealthcare Will Share The Savings: Point-Of-Sale Rebates Coming In 2019
Biggest benefit to manufacturers from the insurer's upcoming program may be relieving public pressure on list prices.